Orgenesis is a premier service provider in the regenerative medicine industry. Orgenesis provides contract development and manufacturing (CDMO) services for many of the world’s leading pharmaceutical and biotech companies, as well as research institutions and hospitals involved in cutting edge cell therapy
Diamond Equity Research LLC is being compensated by Orgenesis Inc. for producing research materials regarding Orgenesis Inc. and its securities. Payment is made in cash and is billed one time and upfront for a six month subscription, which includes one initiation report and one update report. As of 02/10/2018 the issuer had paid us $14,000 for our services, which commenced 07/07/2017. Additional fees may have accrued since then.